Crohn’s Disease
-
Aurobindo’s subsidiary CuraTeQ obtains exclusive rights for BioFactura’s Ustekinumab biosimilar
CuraTeQ has been granted exclusive license rights to commercialize BFI-751 in all major regulated markets including the US, the EU,…
Read More » -
Janssen presents results of biologic therapies in patients with Crohn’s Disease
The SEAVUE study examined a total of 386 patients with moderately to severely active CD patients The Janssen Pharmaceutical Companies…
Read More »